GlobeNewswire EN Nachrichten

 

Equinor (OSE: EQNR, NYSE: EQNR) will, after the annual general meeting on 12 May 2026, commence the second tranche of up to USD 375 million of the share buy-back programme for 2026, as announced in connection with the company's first quarter results on 6 May 2026....

Equinor (OSE:EQNR, NYSE:EQNR) delivered an adjusted operating income* of USD 9.77 billion and USD 2.86 billion after tax* in the first quarter of 2026. Equinor reported a net operating income of USD 8.78 billion and a net income of USD 3.10 billion. Adjusted net income* was USD 3.70 billion, leading to adjusted earnings per share* of USD 1.48....

Key information relating to the cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for first quarter 2026....

Lerøy Seafood Group ASA will present its results for the first quarter of 2026 on Tuesday, 12 May, at Hotel Continental, Stortingsgata 24/26, Oslo at 08:00 CET....

WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced the pricing of its underwritten public offering of 19,730,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,400,000 shares of common stock. The shares of common stock are being sold at a public offering price of $17.75 per share and the pre-funded warrants are being sold at a public offering price of $17.749 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.001 per share exercise price for each pre-funded warrant. In addition, Avalo has granted the underwriters a 30-day option to purchase up to an additional 3,169,500 shares of its common stock on the same terms and conditions. The gross proceeds to Avalo from the offering are...

NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (known as DNTH212 outside Greater China)....

— Board of Directors Approves $100 Million Share Repurchase Program — — Board of Directors Approves $100 Million Share Repurchase Program —...

GUADALAJARA, Mexico, May 05, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger traffic figures for April 2026, compared with April 2025....

See attached....

COLUMBUS, Ohio, May 05, 2026 (GLOBE NEWSWIRE) -- Bread Financial Holdings, Inc. (NYSE: BFH) (“Bread Financial” or the “Company”) announced today the pricing of its previously announced underwritten public offering of 4,800,000 depositary shares (the “Depositary Shares”), each representing a 1/40th interest in a share of its 8.875% Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B, par value $0.01 per share (the “Series B Preferred Stock”), with a liquidation preference of $25 per Depositary Share (equivalent to $1,000 per share of Series B Preferred Stock). In addition, pursuant to the underwriting agreement, dated May 5, 2026, between the Company and Morgan Stanley & Co., LLC, RBC Capital Markets, LLC, UBS Securities LLC, Wells Fargo Securities, LLC and Keefe, Bruyette & Woods, Inc., as representatives for the underwriters named therein (the “Underwriters”), the Company granted the Underwriters an option to purchase up to an additional 720,000 Depositary Shares at ...

FORT LAUDERDALE, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”), today announced that on April 29, 2026, it received a notice from NYSE Regulation (the “NYSE”) indicating that the Company is not currently in compliance with the NYSE's continued listing standards related to minimum shareholders' equity. In accordance with NYSE requirements, the Company is required to submit a plan by May 29, 2026, outlining the actions it has taken or will take to regain compliance. If the plan is accepted, the Company may be granted a cure period extending through January 29, 2027 to restore compliance with the continued listing standards....

LEPAS Milan Public Days showcased the brand's fusion of elegant design, advanced technology, and lifestyle during Milano Design Week...

Not for distribution to U.S. newswire services or dissemination in the United States....

At Auto China 2026, LEPAS unveiled its NEV lineup and kicked off its global “Year of Delivery.”...

MEXICO CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Aeromexico acknowledges the efforts and leadership of Mexico's authorities, led by the Secretaria de Relaciones Exteriores (SRE), Secretaria de Infraestructura, Comunicaciones y Transportes (SICT), and the Agencia Federal de Aviacion Civil (AFAC), in advancing negotiations with the United States Department of Transportation (DOT)....

LGI Homes, Inc. Reports April 2026 Home Closings...

CICERO, Ill., May 05, 2026 (GLOBE NEWSWIRE) -- Broadwind (Nasdaq: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced that on April 30, 2026, the Company's wholly-owned subsidiary, Broadwind Heavy Fabrications, Inc. (“Heavy Fabrications”) entered into a definitive agreement with IES Infrastructure, a wholly-owned subsidiary of IES Holdings, Inc. (NASDAQ: IESC), under which Heavy Fabrications has sold its production facility in Abilene, Texas (the “Facility”), including real property, equipment, machinery and other items, to IES Infrastructure for an aggregate purchase price of up to $19.5 million in cash and non-cash consideration in the form of a below market lease, subject to certain purchase price adjustments....

SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that three icovamenib abstracts have been selected for late-breaking poster presentations at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans. The presentations include data from icovamenib, the Company's investigational oral menin inhibitor, across both type 1 and type 2 diabetes, highlighting its potential to improve beta cell function and support metabolic health....

CALGARY, Alberta, May 05, 2026 (GLOBE NEWSWIRE) -- Gibson Energy Inc. (TSX:GEI) ("Gibson" or the "Company") announced today the voting results for the election of directors at the Company's hybrid annual meeting of shareholders held on May 5, 2026....

Battalion Oil signs LOI for joint development to accelerate up to eight wells at Monument Draw, sharing capital while retaining operatorship....